B
Bull
Bull · 25%APUS
$2.05
情景价格
$3.870
-0.079 (-2.03%)收盘时
Loading chart…
- High
- 4.100
- Open
- 4.100
- VWAP
- 3.94
- Vol
- 9.07K
- Mkt Cap
- —
- Low
- 3.861
- Amount
- 35.78K
- EV/EBITDA, TTM
- 0.00
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
AI analysis of Apimeds Pharmaceuticals US Inc (APUS)
sellGiven the current price of 3.87, the RSI of 30.157 indicates that the stock is oversold, but the significant year-to-date change of -97.68% and negative net income figures suggest that the company is struggling financially. The recent leadership changes and settlement agreements may provide some hope for recovery, but the risks are substantial, particularly with a projected trajectory indicating a potential future change of +243.47% based on historical patterns, which is speculative at best. The main risk is the company's current liabilities exceeding its assets, leading to a current ratio of 0.00.
估值指标
The current forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for APUS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.507-28GlobenewswireMindChain: The World's First Fully Insured Blockchain Launching Soon
8.507-28NewsfilterMindWave Launches World's First Fully Insured Blockchain
8.505-06NASDAQ.COMApimeds Reaches Settlement with Inscobee, Clearing Path for Merger
- 8.505-05Newsfilter
Apimeds Pharmaceuticals Settles Disputes with Inscobee, Resuming Trading
7.005-04moomooAPIMEDS PHARMACEUTICALS US INC ANNOUNCES SETTLEMENT AGREEMENT WITH INSCOBEE DATED APRIL 24, 2026 - SEC FILING
APUS FAQ — answered by Alphio AI
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.
Given the current price of 3.87, the RSI of 30.157 indicates that the stock is oversold, but the significant year-to-date change of -97.68% and negative net income figures suggest that the company is struggling financially. The recent leadership changes and settlement agreements may provide some hope for recovery, but the risks are substantial, particularly with a projected trajectory indicating a potential future change of +243.47% based on historical patterns, which is speculative at best. The main risk is the company's current liabilities exceeding its assets, leading to a current ratio of 0.00.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。